TECHNE CORPORATION RELEASES UNAUDITED FIRST QUARTER RESULTS FOR FISCAL YEAR 2008

Minneapolis/October 24, 2007/--Techne Corporation’s (NASDAQ: TECH) consolidated net earnings for the quarter ended September 30, 2007 increased 17.5% to $23.1 million or $.58 per diluted share compared with $19.6 million or $.50 per diluted share for the quarter ended September 30, 2006. Net earnings as a percentage of net sales improved from 37.5% in the first quarter of last year to 39.8% for the quarter ended September 30, 2007. The improvement in net earnings was mainly due to increased consolidated net sales. The favorable impact on consolidated net earnings of the change in exchange rates used to convert R&D Europe results from British pounds to U.S. dollars was $403,000 ($.01 per diluted share) for the quarter ended September 30, 2007. 

Consolidated net sales for the quarter ended September 30, 2007 were $58.0 million, an increase of 10.8% from the same prior-year quarter. Consolidated net sales were favorably affected by the strength of the British pound as compared to the U.S. dollar. Excluding the effect of changes in foreign currency exchange rates, consolidated net sales increased 8.6% for the quarter ended September 30, 2007 from the quarter ended September 30, 2006.

Biotechnology net sales, which include sales by R&D Systems’ Biotechnology Division, R&D Systems China and BiosPacific, for the quarter ended September 30, 2007 were $38.9 million, an increase of 8.2% from the same prior-year quarter. R&D Europe’s net sales for the quarter were $15.4 million, an increase of 19.5% from the same prior-year quarter. In British pound sterling, R&D Europe’s net sales increased 10.7% for the quarter.  Hematology net sales for the quarter were $3.7 million, an increase of 4.4%.

Gross margins were 79.1% and 78.5% in the first quarters of fiscal 2008 and 2007, respectively. The increase in gross margins was due to higher margins in Europe due to favorable exchange rates and changes in sales mix as a result of higher sales growth in the Biotechnology Division as compared to the sales growth in the lower margin Hematology Division.

Selling, general and administrative expenses for the quarter ended September 30, 2007 increased $1.0 million (14.5%). The increase resulted from the change in foreign currency exchange rates used to convert British pounds to U.S. dollars ($170,000), increased profit sharing of $205,000 and R&D China selling, general and administrative expenses of $99,000.  The remainder of the increase was due mainly to annual wage and salary increases.

The effective tax rate was 33.6% for the quarter ended September 30, 2007 as compared to 33.9% for the quarter ended September 30, 2006. Without significant business developments, the Company expects its fiscal 2008 effective income tax rate to range from approximately 33.5% to 34.5%.

Forward Looking Statements:
This earnings release contains forward-looking statements within the meaning of the Private Litigation Reform Act.  These statements, including the Company’s expectations as to income tax rates, involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company’s actual results: the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company’s customers, the impact of the growing number of producers of biotechnology research products and related price competition, the retention of hematology OEM and proficiency survey business, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.  For additional information concerning such factors, see the Company’s annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission.  We undertake no obligation to update or revise any forward-looking statements we make in this release due to new information or future events.  Investors are cautioned not to place undue emphasis on these statements.

*  *  *  *  *  *  *  *  *  *  *  *  *  *

Techne Corporation has two operating subsidiaries:  Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty manufacturer of biological products.  R&D Systems has two subsidiaries, BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. R&D China and R&D Europe distribute biotechnology products.

Contact:  Greg Melsen, Chief Financial Officer
                Kathy Backes, Controller 
                (612) 379-8854

TECHNE CORPORATION CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited)
ASSETS	9/30/07	6/30/07
Cash and equivalents	$144,745	$135,485
Short-term available-for-sale investments	36,249	29,289
Trade accounts receivable	30,673	29,559
Other receivables	1,362	1,407
Inventory	9,281	8,757
Other current assets	8,899	8,341
Current assets	231,209	212,838
Available-for-sale investments	97,851	91,433
Property and equipment, net	93,385	91,535
Goodwill and intangible assets, net	29,879	30,167
Other non-current assets	28,732	28,871
Total assets	$481,056	$454,844
LIABILITIES
Current liabilities	$ 14,800	$ 17,193
Stockholders’ equity	466,256	437,651
Total liabilities and equity	$481,056	$454,844